Navigation Links
BioRelix and Dalton Medicinal Chemistry Expand and Renew Research Agreement to Capitalize on Riboswitches
Date:3/23/2009

BioRelix, pioneers in the discovery and development of Riboswitch based therapeutic agents, and Dalton Medicinal Chemistry have jointly announced an expansion and renewal of their exclusive worldwide collaboration and agreement to discover and develop new therapeutics.

New Haven, CT and Toronto, Canada (PRWEB) March 23, 2009 -- BioRelix, pioneers in the discovery and development of Riboswitch based therapeutic agents, and Dalton Medicinal Chemistry have jointly announced an expansion and renewal of their exclusive worldwide collaboration and agreement to discover and develop new therapeutics.

Dalton Medicinal Chemistry will apply their proprietary insights to the design and synthesis of new classes of compounds against selected Riboswitch targets. BioRelix will advance these compounds with their cutting edge array of biological assays and thorough knowledge of Riboswitch drug discovery and development.

Brian Dixon, BioRelix CEO commented, "We are pleased to have the opportunity to expand and renew our productive relationship with the creative team at Dalton Medicinal Chemistry. We are confident their expertise, insights and commitment to high quality medicinal chemistry, coupled with our propriety and leading position on Riboswitches, will continue to deliver value in important new medicines."

Judd Berman, Co-founder of Dalton Medicinal Chemistry, said: "We are delighted to work further with BioRelix in the discovery and development of much needed new anti-infective agents. The team at BioRelix has clearly established a remarkably innovative and fundamentally groundbreaking approach to anti-infectives and we are pleased to be with them at the forefront of this medicinal chemistry and drug discovery."

About BioRelix:
BioRelix, Inc. is a drug discovery and development company focused on identifying new anti-infective drug treatments. BioRelix is building a portfolio of anti-infective product candidates based on novel patented RNA targets, termed Riboswitches, which were identified by the laboratory of BioRelix co-founder, Ronald Breaker, Ph.D., Howard Hughes Investigator and Henry Ford II Professor at Yale University. BioRelix investors include CHL Medical Partners, Novartis Venture Fund, Aisling Capital, New Leaf Venture Partners, Elm Street Ventures and Alexandria Real Estate Equities.

About Dalton Medicinal Chemistry:
Dalton Medicinal Chemistry is a drug discovery company focused on the design, synthesis and advancement of new chemical entities in partnership with Biotech and Pharma.

Contacts:
BioRelix, Inc.
Brian Dixon
203-785-9282
www.biorelix.com

Dalton Medicinal Chemistry
Peter Pekos
416-661-2102
www.dalton.com

###

Read the full story at http://www.prweb.com/releases/BioRelix/Dalton_Medicinal/prweb2255524.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. PartsSource President & CEO A. Ray Dalton Wins Innovation in Business Award
2. PartsSource President & CEO A. Ray Dalton Named Harvard School of Business Entrepreneur of the Year
3. Bruker Daltonics Showcasing Novel Proteomics Solutions Based on Mass Spectrometry at the 7th HUPO World Congress 2008
4. Dalton Pharma Services and Boehringer Ingelheim (Canada) Ltd. Announce the Renewal of their Chemistry Services Agreement
5. Non-medicinal treatment touted for pre-schoolers with ADHD
6. Nonmedicinal treatment touted for preschoolers with ADHD
7. ATIR Classified as "Cell Based" Medicinal Product by the EMEA
8. Indian medicinal plant Acanthus ilicifolius may combat liver cancer
9. Oriental Medicinal Herb Garden Dedication
10. An Alternative to Medicinal Marijuana
11. MS drug development agreement based on WEHIs medicinal chemistry
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
BioRelix and Dalton Medicinal Chemistry Expand and Renew Research Agreement to Capitalize on Riboswitches 
(Date:5/25/2016)... ... May 25, 2016 , ... The Bank of America Charitable Foundation has ... help provide veterans a pathway to employment and successful careers in healthcare. On Wednesday, ... Nick Hallack, President and CEO of Medisend, parent organization and home of the General ...
(Date:5/25/2016)... ... May 25, 2016 , ... New studies published today ... workers across 15 states. The outcomes examined in these studies include recovery of ... and satisfaction with medical care. , “The goal of the studies is to ...
(Date:5/25/2016)... ... 2016 , ... Today Omega Institute, a leading destination for yoga education in ... opportunities in the growing field of yoga therapy . Yoga therapy adapts ... specific health issues—including injuries, illnesses, and temporary or chronic health conditions. , “Yoga therapy ...
(Date:5/25/2016)... Washington, D.C (PRWEB) , ... May 25, 2016 ... ... of family planning services and products in the developing world, is pleased to ... couples, helped prevent over 5 million unwanted pregnancies, almost 14,000 maternal deaths and ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... supporting the real time adjudication of medical service claims by Pharmacy Benefit Managers ... current medical claims management software. The TransactRx Cross Benefit Clearinghouse receives standard professional ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... Non-invasive diagnostic test realizes the ... ,Technology to be presented at Yissum’s booth, at IATI-BIOMED ... Company of the Hebrew University of Jerusalem announced ... Aurum Ventures MKI, the technology investment arm of Morris ... approach for early detection of multiple diseases by analyzing ...
(Date:5/23/2016)... -- Gamida Cell, a leader in cellular ... orphan genetic diseases, announced today it has been awarded ... Israel Innovation Authority (formerly the Office of the Chief ... The mission of the Israel Innovation Authority is to ... and technology, while stimulating economic growth. The ...
(Date:5/23/2016)... STAMFORD, Conn. , May 23, 2016 /PRNewswire/ ... Company has entered into an agreement with Egalet ... various patent claims. As part of the agreement ... rights, and will enable all three companies to ... abuse-deterrent properties. "This agreement reflects the ...
Breaking Medicine Technology: